ReCor Medical Begins ACHIEVE Post-Market Study With Its Generation-2, Ultrasound-Based PARADISE™ Renal Denervation System
2/14/2013 10:48:33 AM
More...
|
ReCor Medical Receives CE Mark for its Generation 2, Ultrasound-based PARADISE™ Renal Denervation System
1/24/2013 9:43:49 AM
More...
|
ReCor Medical Reports 100% Responder Rate at One-Year Follow-up in Clinical Trial of Its Ultrasound-Based PARADISE™ Renal Denervation System for Treating Resistant Hypertension, a Major Risk Factor for Cardiovascular Disease
11/5/2012 9:51:04 AM
More...
|
ReCor Medical Expands Its Medical Advisory Board
9/28/2012 10:47:08 AM
More...
|
ReCor Medical Reports Impressive Six-Month Follow-Up Data for Its Ultrasound-Based PARADISE™ Renal Denervation System for Treating Resistant Hypertension
6/15/2012 11:10:52 AM
More...
|
ReCor Medical Completes REDUCE Pilot Clinical Study of Its PARADISE™ Ultrasound Transcatheter Renal Denervation System for Treating Resistant Hypertension
5/14/2012 9:49:40 AM
More...
|
ReCor Medical Discloses New Data From Clinical Study of its PARADISE™ Ultrasound Transcatheter Renal Denervation System for Treating Resistant Hypertension
4/9/2012 12:28:45 PM
More...
|
ReCor Medical Announces CE Mark Approval for Its Novel PARADISE™ Ultrasound Transcatheter Renal Denervation System
2/21/2012 6:34:45 AM
More...
|
ReCor Medical Announces Successful First-in-human Clinical Case Using Ultrasound to Cure Mitral Regurgitation (MR)
9/22/2010 11:26:30 AM
More...
|